Novo Nordisk Shares Gain 2.4% Following Additional CagriSema Weight-Loss Trial Analyses
Novo Nordisk (NVO) shares rose 2.4% after presenting additional REDEFINE 1 trial data showing 25.4% average weight loss for early responders to CagriSema. The trial, excluding type 2 diabetes patients, found 67.8% of participants lost at least 5% weight in 8 weeks. CagriSema combines cagrilintide and semaglutide. Novo Nordisk expects a US regulatory decision in Q4 2026.
How this was made

The 30-second read
Why it matters
The findings highlight a strong efficacy signal for the investigational CagriSema combo, potentially influencing the upcoming US regulatory decision in Q4 2026.
Market read
New trial data may drive short‑term price appreciation and affect sector sentiment ahead of the regulatory review.
What to watch
Higher gastrointestinal adverse events (79.6%) could temper enthusiasm and affect adoption rates.
Background
Novo Nordisk disclosed additional analyses from its REDEFINE 1 trial at ObesityWeek 2026, focusing on early‑response weight‑loss outcomes.
Ticker impact
Novo Nordisk presented new REDEFINE 1 trial analyses showing early responders achieved 25.4% weight loss at 68 weeks, a first‑time disclosure of these results.
potential upside as investors price in stronger efficacy signals
First report of detailed efficacy data; early‑response subgroup shows markedly higher weight loss, which can drive market optimism ahead of the Q4 US regulatory decision.
Market effects
Positive signal for the obesity‑treatment segment may lift peers in metabolic‑disease space.
European pharma stocks could see modest gains as a leading Danish company reports encouraging data.
Global investors tracking obesity therapeutics will monitor the upcoming US regulatory decision.
Counterpoint
The data are exploratory and may not translate into regulatory approval; investors should weigh the risk of unmet expectations.
Key entities
- companyNovo Nordisk
Danish pharmaceutical firm developing the obesity treatment CagriSema.

